
Alethio raises $90 million to develop targeted treatments for blood cancers
Alethio Therapeutics logoAlethio Therapeutics has raised $90 million (£67 million) in a Series A round to develop targeted treatments for a group of blood cancers called myeloproliferative neoplasms. The Oxford spin-out announced the financing on 5 November. Sofinnova Partners and RA Capital co-led the round, alongside founding investor Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford.
The lead programme, ATX-011, is an antibody designed to bind G6B, a protein found on platelets and the cells that make them. Platelets help blood clot. In essential thrombocythaemia, the body makes too many of them, increasing the risk of harmful clots. ATX-011 aims to bring platelet counts down by helping the body clear platelets from the blood.
The company also sees a wider research opportunity. It says G6B is unusually present on stem cells that start these cancers, but not on healthy stem cells, and on cells involved in bone-marrow scarring. Those findings support further study of whether targeting the protein could affect the underlying disease.
Alethio is still carrying out the work needed before seeking permission to start human trials. The new money is intended to take ATX-011 through Phase 1/2a studies in essential thrombocythaemia and prepare it for later-stage testing. It will also support additional programmes as they move toward applications to begin clinical studies.
Professors Adam Mead and Beth Psaila founded the company from University of Oxford research. Dr Rohit Batta is its chief executive. The company says preclinical ATX-011 data have been selected for an oral presentation at the 2026 American Society of Hematology meeting. Clinical safety and effectiveness remain to be established.
DTT summary based on Alethio Therapeutics's report. The full article is on the publisher's site.
Additional reporting
$90 million Series A announced 5 November 2026.
Sofinnova Partners, RA Capital, Oxford Science Enterprises, Cancer Research Horizons, University of Oxford.
Human safety and effectiveness are not established.
This announcement is a $90 million Series A. The primary release does not state a separate cumulative funding total or valuation.